Adamas Announces USFDA Acceptance of New Drug Application for Levodopa-induced Dyskinesia in Patients with Parkinson's Disease Life Science Investing
Adamas Announces U.S. FDA Acceptance of ADS-5102 New Drug Application for the Treatment of Levodopa-induced Dyskinesia in Patients with Parkinson's Disease Life Science Investing
Fibrocell Announces FDA Fast Track Designation of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa Pharmaceutical Investing
CymaBay Therapeutics Announces Successful Completion of Scientific Advice Discussions with the European Medicines Agency for Arhalofenate Pharmaceutical Investing
Cascadian Therapeutics Announces 2017 Outlook and Recent Drug Portfolio Progress Life Science Investing
Ocera Announces Successful Phase 1 Clinical Study of Orally-Administered OCR-002 in Patients with Cirrhosis Life Science Investing
Q BioMed Inc. to Present at Biotech Showcase 2017 in San Francisco Jan 9 – 11th Life Science Investing
OncoMed Initiates Enrollment of Phase 1b Clinical Trial for Metastatic Colorectal Cancer Patients Life Science Investing
IntelGenx Announces Definitive Agreement with Chemo Group for a Generic CNS Tablet Life Science Investing
